{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-019330","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2022-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.992167+00:00","generated_at":"2026-06-23T05:07:00.933404+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cyclerion cuts 45% of workforce, focuses on mitochondrial disease after positive MELAS data","bullets":["Workforce reduced by ~45% (13 employees) in Q4 2022 to align with mitochondrial disease strategy.","Estimated severance charge of ~$1.9M in Q4 2022; expects annual cash savings of ~$4.1M.","Plans to meet with FDA in Q4 2022 to discuss CY6463 development path for MELAS.","ADv study enrollment capped; data expected H1 2023; CIAS program CY3018 to seek partnership.","Will out-license olinciguat and praliciguat; praliciguat already licensed to Akebia for milestones/royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-019330","json":"https://secwatch.observer/filing/0000950170-22-019330.json","markdown":"https://secwatch.observer/filing/0000950170-22-019330.md","text":"https://secwatch.observer/filing/0000950170-22-019330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022019330/0000950170-22-019330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022019330/cycn-20221006.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:07:00.933404+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}